Case series of acute cholecystitis associated with the use of Glucagon-Like Peptide-1 Receptor agonists reported to the US Food and Drug Administration.

Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration – JAMA Internal Medicine (free for a limited period)

Related: Meta-analysis of randomized trials: GLP1 receptor agonists increase the risk of gallbladder and biliary diseases (RR, 1.37; 95% CI, 1.23-1.52).